1. Supplemental Figure 5 v A Idarubicin 100 nM Idarubicin 300 nM B C D
Mcl1
Tubulin
100nM
300nM 3 6 9 12
Incubation (h)
p53
1000nM C
DMSO
DMSO
DMSO
Incubation (h) 1 2 3 4 6 1 2 3 4 6 1 2 3 4 6
BCL-2
BCL-XL
MCL1
Tubulin
Idarubicin 1μM
Ara-C 100μM
Daunorubicin 1μM D
Incubation
time (h) 2 4 6 2 4 6 2 4 6
Mcl1
Tubulin
100nM
300nM
1000nM

2. Supplemental Figure 5
(A) FDM cells lacking both Bax and Bak were incubated with 100nM and 300nM idarubicin. Noxa and Puma gene expression were assayed by RT-PCR. Results represent the mean +/- SEM of 4 independent experiments.
(B) Bak/Bax double knockout FDM cells were exposed to idarubicin at low (100nM), intermediate (300nM) or high (1000nM) concentrations for up to 12 hours. 100nM idarubicin resulted in p53 up-regulation but had no effect on Mcl-1 expression. 1000nM idarubicin caused rapid loss of Mcl-1, but no Tp53 activation. Intermediate concentrations resulted in both up-regulation of Tp53 and down-regulation of Mcl-1.
(C) MV4;11 cells were exposed to idarubicin (1µM) or Ara-C (100µM). Idarubicin rapidly suppressed MCL1 without changes to BCL-2 or BCLXL levels. No such changes were seen with cytarabine.
(D) p53 knockout FDM cells were exposed to increasing concentrations of idarubicin for up to 6 hours. Mcl1 was rapidly suppressed by higher ( nM) but not lower concentrations of idarubicin (100 nM).